Immix Biopharma, Inc. IMMX Deferred Tax Assets Tax Federal State Research Credit Carryforwards
Deferred Tax Assets Tax Federal State Research Credit Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept IMMX:DeferredTaxAssetsTaxFederalStateResearchCreditCarryforwards.
The official record: Immix Biopharma, Inc.’s 10-K/A, filed March 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s deferred tax assets tax federal state research credit carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s deferred tax assets tax federal state research credit carryforwards?
- Immix Biopharma, Inc. (IMMX) reported deferred tax assets tax federal state research credit carryforwards of $4.96M in Q4 2025.
- What does deferred tax assets tax federal state research credit carryforwards mean?
- This represents the value of tax credits earned from research and development activities that can be carried forward to reduce future tax liabilities. For clinical-stage biopharmaceutical companies, this asset reflects the potential tax benefit of historical R&D investment. It serves as a indicator of the company's ability to offset future taxable income through innovation-related tax incentives.